Investment Thesis
GENELUX is a pre-revenue/development-stage pharmaceutical company with near-zero revenue ($8K), unsustainable operating losses ($9.2M), and negative free cash flow ($7.0M), indicating runway of approximately 1.5 years at current burn rates. While the company maintains adequate liquidity ($9.3M cash, 3.68x current ratio), the complete absence of commercial revenue, deteriorating cash position, and escalating net losses represent extreme fundamental weakness.
Strengths
- Adequate short-term liquidity with $9.3M cash reserves and 3.68x current ratio
- Moderate leverage with 0.40x debt-to-equity ratio reducing financial stress
- Positive insider activity with 5 Form 4 filings in 90 days
Risks
- Near-zero revenue ($8K) indicates no commercial product sales or severe revenue collapse
- Operating cash burn of $6.1M annually with only 1.5 years of cash runway remaining
- Unsustainable operating losses of $9.2M with negative net margin of -111,600%
- No visible path to profitability; company dependent on clinical development success
Key Metrics to Watch
- Cash and equivalents decline rate relative to operating burn
- Revenue generation timing and magnitude from any approved programs
- Operating expense reduction or maintenance of current burn rate
Financial Metrics
Revenue
8.0K
Net Income
-8.9M
EPS (Diluted)
$-0.20
Free Cash Flow
-7.0M
Total Assets
32.4M
Cash
9.3M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-114,637.5%
Net Margin
-111,600.0%
ROE
-39.0%
ROA
-27.6%
FCF Margin
-87,250.0%
Balance Sheet & Liquidity
Current Ratio
3.68x
Quick Ratio
3.68x
Debt/Equity
0.40x
Debt/Assets
29.2%
Interest Coverage
N/A
Long-term Debt
9.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T08:20:29.544712 |
Data as of: 2026-03-31 |
Powered by Claude AI